Active Not RecruitingNCT06069843
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Medication studyAges 50–90United States
Understand this study
Who could participate?
Listed age limits: 50 years to 90 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 1, 2024
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 15
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 50 Years to 90 Years
- Official registry ID
- NCT06069843
- Official title
Show the full official title
KET-MCI: An Open-label Trial of Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Does this study involve medication?
Yes. The study involves medication, including IV Ketamine.
Who can participate?
Listed age limits: 50 years to 90 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
